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The proprotein convertase subtilisin/kexins (PCSKs) are a serine endopeptidase family. PCSK members cleave amino
acid residues and modulate the activity of precursor proteins. Evidence from patients and animal models carrying
genetic alterations in PCSK members show that PCSK members are involved in various metabolic processes. These
studies further revealed the molecular mechanism by which genetic alteration of some PCSK members impairs
normal molecular and physiological functions, which in turn lead to cardiovascular disease. High-density lipoprotein
(HDL) is anti-atherogenic as it removes excessive amount of cholesterol from blood and peripheral tissues. Several
PCSK members are involved in HDL metabolism. PCSK3, PCSK5, and PCSK6 process two triglyceride lipase family
members, endothelial lipase and lipoprotein lipase, which are important for HDL remodeling. Recent studies in our
lab found evidence that PCSK1 and PCSK9 are also involved in HDL metabolism. A mouse model carrying an amino
acid substitution in PCSK1 showed an increase in serum apolipoprotein A1 (APOA1) level. Another mouse model
lacking PCSK9 showed a decrease in APOE-containing HDL. In this review, we summarize the role of the five PCSK
members in lipid, glucose, and bile acid (BA) metabolism, each of which can influence HDL metabolism. We
propose an integrative model in which PCSK members regulate HDL metabolism through various molecular
mechanisms and metabolic processes and genetic variation in some PCSK members may affect the efficiency of
reverse cholesterol transport. PCSK members are considered as attractive therapeutic targets. A greater
understanding of the molecular and physiological functions of PCSK members will improve therapeutic strategies
and drug efficacy for cardiovascular disease where PCSK members play critical role, with fewer adverse effects.
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In the past two decades nine members of the highly con-
served bacterial subtilisin- and yeast kexin-like serine
protease family have been discovered and characterized.
Analyses in animal models and in patients with muta-
tions in PCSK members have revealed the molecular
mechanism by which genetic alterations in PCSK mem-
bers affect molecular and physiological functions in vari-
ous metabolic diseases and endocrinological defects
[1-4]. However, our understanding of how PCSK mem-
bers are involved in HDL metabolism is still limited. The
HDL biology has been updated in many reviews during
the past decades [5-10], and we briefly summarize sev-
eral key points: The major function of HDL is to remove* Correspondence: ron.korstanje@jax.org
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distribution, and reproduction in any mediumexcessive amounts of cholesterol from peripheral tissues
via a mechanism called reverse cholesterol transport
(RCT). HDL takes up cholesterol from low-density lipo-
protein (LDL) or macrophage foam cells in atheroscler-
otic lesions and then delivers it to the liver for recycling
or excretion. As a high level of HDL correlates with low
risk of atherosclerotic cardiovascular diseases, HDL is
considered an anti-atherogenic factor. Thus, abnormal
regulation of HDL synthesis, remodeling and catabolism
causes reduced HDL cholesterol concentration and HDL
function, which then promotes the risk or progression of
the disease.
Some PCSK members were previously found to be im-
portant in HDL metabolism. Data from our lab shows
that PCSK1 is involved in regulating the levels of serum
apolipoprotein A1 (APOA1), which is the major protein
for HDL formation and remodeling (Choi et al., in prepar-
ation). PCSK3, PCSK5 and PCSK6 process two membersentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Official and alternative protein name of the nine
PCSK members












•MBTPS1: membrane-bound transcription factor peptidase, site 1.
Choi and Korstanje Biomarker Research 2013, 1:27 Page 2 of 8
http://www.biomarkerres.org/content/1/1/27in the triglyceride (TG) lipase family: endothelial lipases
(EL) and lipoprotein lipases (LPL) [11] that play important
role in regulating the HDL cholesterol concentration.
We have also shown that PCSK9 influences HDL chol-
esterol concentration by regulating APOE-containing HDL
levels [12].
Protein structure and principle of PCSK
PCSK proteins consist of several peptide domains: a signal
peptide/transmembrane domain at the amino-terminus,
a prosegment domain, a catalytic domain, a P domain, a
Cys-rich domain, a cytoplasmic tail, and a Cys-His-rich
domain at the carboxyl-terminus [1]. The catalytic domain
is the most conserved sequence and the identity is about
35% and the presence of first three domains is common
between the five PCSK members (Figure 1). The PCSK
family consists of two groups divided by amino acid cleav-
age sites: typical and atypical (Table 1) [13]. PCSK1, PCSK3,
PCSK5, and PCSK6 are typical members and cleave single
or paired basic amino acids with the motif (R/K)Xn(R/K)↓,
where the arrow indicates the cleavage site and Xn corre-
sponds to a 0-, 2-, 4-, or 6-amino-acid spacer [2]. PCSK9
is an atypical member and cleaves non-basic residues at
the C-terminal end of the motif RX(L/V/I)X↓, where X
represents any amino acid except for cysteine and proline
[14]. PCSK9 cleaves itself at its internal (V/I/L)FAQ152↓
sequence, and then acts as a binding protein for cell sur-
face receptors [15,16].
PCSKs and lipid metabolism
Some PCSK members are involved in regulating the activ-
ity of important modulators of lipid metabolism (Figure2A)
[3]. The potential role for PCSK1 in lipid metabolism
was observed in a study using a loss-of-functional mouse
model that carries a mutation in Pcsk1 (Choi et al., inFigure 1 Schematic illustration for the protein structure; typical and a
and PCSK9. The figure illustrates the peptide domains and cleavage site o
members consist of several peptide domains: a signal peptide/transmembr
a catalytic domain (Cat), a P domain (P), a Cys-rich domain (Cys), a cytoplas
terminus. Three protein domains are common between five PCSK member
and PCSK6) cleaves single or paired basic amino acids with the motif (R/K)X
corresponds to a 0-, 2-, 4-, or 6-amino-acid spacer at (R/K)Xn(R/K)↓, meanwh
C-terminal end of the motif (V/I/L)FAQ↓.preparation). The mutation was introduced by treating
mice with N-ethyl-N-nitrosourea (ENU), a chemical that
induces A- > G transition, which led to an amino acid
substitution from asparagine (N) to aspartic acid (D) at
position 222. The mutation reduces enzymatic activity
of PCSK1 in cleaving downstream substrates [17,18].
In the PCSK1 mutant male mice on a chow-diet for
8 weeks, serum apolipoprotein A1 (APOA1), which is
the major component of HDL, was 1.5-2.0 fold increased
(Figure 2A(1)), but fasting serum HDL cholesterol con-
centration in the PCSK1 mutant was similar to wild-
type controls. In the PCSK1 mutant mouse livers, APOA1
concentration was ~2.0 fold decreased, while Apoa1 ex-
pression was similar, suggesting that PCSK1 is involved
in regulating serum APOA1 concentration and that
PCSK1 mutant might increase APOA1 secretion from
the liver to serum. It is still unknown why HDL choles-
terol concentration is not effected despite the increase
in APOA1.typical cleavage activies of human PCSK1, PCSK3, PCSK5, PCSK6,
f human PCSK1, PCSK3, PCSK5, PCSK6, and PCSK9. The five PCSK
ane domain (S/T) at the amino-terminus, a pro-segment domain (Pro),
mic tail (Cyt), and a Cys-His-rich domain (CHRD) at the carboxyl-
s: S/T, Pro, and Cat domains. Typical members (PCSK1, PCSK3, PCSK5,
n(R/K)↓, where the arrow indicates the cleavage site and Xn
ile atypical member (PCSK9) cleaves non-basic residues at the
Figure 2 The role of PCSK members in various metabolic processes and disorders. The figure illustrates the role of PCSK1, PCSK3, PCSK5,
PCSK6, and PCSK9 in lipid (A), glucose (B), and BA (C) metabolism. Arrows with 2 different types of lines indicate the relationship between
factors: solid lines with arrow indicate a “positive influence” and dotted lines with arrow indicate a “negative influence.” For example, PCSK3, 5,
and 6 inactivates EL (Figure 2A(2)). In contrast, solid lines with arrow indicate a “positive influence.” For example, PCSK9 inhibition decreases
serum APOB level (Figure 2(5)).
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tabolism by modulating two members of the TG lipase
family. The three PCSK members negatively influences
EL activity by cleaving a carboxyl-terminal 18 kDa frag-
ment in EL to suppress the enzymatic activity of EL
(Figure 2A(2)) [19]. EL cleavage was induced by transient
expression of PCSK3, PCSK5, and PCSK6 in HEK293 cells
[20]. PCSK3 may also negatively influence EL activity
through angiopoeitin-like protein 3 (ANGPTL3) (Figure 2A
(3)). Adenoviral transduction of PCSK3 in hepatocytes
led to less cleavage product and increased full-length
ANGPTL3 [11]. ANGPTL3 inhibited ~60% of EL activity
by transfecting a plasmid expressing murine ANGPTL3
into HEK293 cells stably expressing EL [11]. Lipoprotein
lipase (LPL) is another member of the TG lipase family
that is similarly inactivated by PCSK-mediated proteolytic
cleavage (Figure 2A(4)) [21]. Transient expression of PCSK3,PCSK5, and PCSK6 induced LPL cleavage in HEK293
cells [20].
The first work that linked PCSK9 with lipid metabol-
ism was published by Abifadel and colleagues 10 years
ago. Gain-of-function mutations in PCSK9 were found
in familial autosomal dominant hypercholesterolemia
patients [22]. The mutations increase LDLR degradation
and decrease LDL clearance, which results in an increase
in circulating LDL. PCSK9 positively regulates APOB
concentration (Figure 2(5)) and inhibition of PCSK9
leads to an increase of LDLR (Figure 2A(6)) and APOB-
containing LDL particles are more rapidly cleared.
PCSK9 also promotes degradation of the VLDL receptor
(VLDLR) and APOE receptor type 2 (LRP8), both of
which are important in TG and VLDL metabolism.
PCSK9 negatively regulates VLDL concentration through
the two receptors (Figure 2A(7)). Ectopic expression of
Choi and Korstanje Biomarker Research 2013, 1:27 Page 4 of 8
http://www.biomarkerres.org/content/1/1/27the PCSK9 gene in HEK293 cells reduced the levels of
LRP8 and VLDLR, while PCSK9 inhibition in CHO-1
and HEK293 cell lines increased the levels of VLDLR
[23].
PCSKs and glucose metabolism
PCSK1 and PCSK9 are involved in glucose metabolism
(Figure 2B) [1]. PCSK1 and PCSK9 positively regulate
pro-insulin conversion to insulin by proteolytic cleavage
in the pancreas. A non-synonymous single nucleotide
polymorphism in human PCSK1 (rs6232) substitutes as-
paragine with aspartic acid at codon 221 (N221D).
Transfecting recombinant N221D PCSK1 protein in hu-
man embryonic kidney 293 cells reduces the proteolytic
cleavage of its substrate [24]. The rs6232 variant is asso-
ciated with an increase in fasting blood glucose level and
a decrease in pancreatic β-cell function and insulin re-
sistance [25]. Insulin was decreased in the pancreas of
PCSK9 KO C57BL/6 males, and the males exhibited
hyperinsulinemic, hyperglycemic, and glucose-intolerant
phenotypes [26].
PCSKs and BA metabolism
PCSK1 and PCSK5 are involved in BA metabolism
(Figure 2C) and positively regulate CCK in the small
intestine by converting procholecystokinin (proCCK) to
CCK [27]. An immunohistochemical analysis and an
in vitro cleavage assay showed that PCSK1 co-localizes
with proCCK and positively regulates proCCK level.
The uncleaved proCCK level was increased and the
cleaved CCK level was decreased in the small intestine
of mice lacking PCSK1 compared to wild-type control
mice [28]. Treating cultured mouse small intestinal
cells with small-interfering (si) RNA against Pcsk5 sig-
nificantly reduced the secretion of cleaved CCK into
the cell culture medium [29]. The secretion of CCK
from the small intestine stimulates BA secretion from
the gall bladder to the gut. BAs promote lipid absorption
and modulate cholesterol levels through enterohepatic
circulation. Defects in BA metabolism cause jaundice of
the eye and skin.
PCSKs and HDL metabolism
PCSK3, PCSK5, and PCSK6 are involved in HDL metab-
olism by modulating EL and LPL. EL is expressed on the
surface of vascular endothelial cells and hydrolyzes
phospholipids in HDL. Over-expression of EL in mice
leads to a decrease in HDL cholesterol concentration
while mice lacking EL show elevated HDL cholesterol
concentration (Figure 3(1)) [30]. LPL activation by
treating rats with LPL inducing reagent (NO-1886) in-
creased HDL cholesterol concentration [31], showing
that LPL activity positively correlates with serum HDL
cholesterol concentration (Figure 3(2)). Recent animalstudies, including ours, showed that PCSK9 is involved
in HDL metabolism. PCSK9 KO male mice on a C57BL/
6 background and fed a chow diet exhibited a 30% re-
duction of HDL cholesterol concentrations [32]. C57BL/
6 males fed a high fat diet and then treated with a Pcsk9
antisense oligonucleotide inhibitor for 6 weeks showed a
54% reduction in HDL cholesterol concentration [33]. In
male cynomolgus macaques, treatment with neutralizing
antibodies against PCSK9 reduced HDL cholesterol con-
centrations for the first seven days of treatment [34].
Data from our lab shows the molecular mechanism in
which PCSK9-mediated HDL regulation is mainly through
low-density lipoprotein (LDLR) [12]. PCSK9 inhibition
increases LDLR level, suggesting the negative relation-
ship between PCSK9 and LDLR (Figure 3(3)). Increased
LDLR subsequently induces the binding of LDLR to APOE
in HDL and thereby leads to rapid HDL clearance. In mice,
HDL is the primary cholesterol carrier and the majority of
cholesterol is enriched in APOE-containing HDL particles
so that reduced level of APOE-containing HDL in the
PCSK9 KO mice is likely to be a cause of reduced HDL
cholesterol concentration. Thus, LDLR negatively influ-
ences HDL cholesterol concentration (Figure 3(4)).
Normal regulation of insulin, glucose, hormones, and
lipids is important for HDL homeostasis, which involves
synthesis, action, and elimination of HDL lipoproteins
[35,36]. Mutations in PCSK1 and PCSK5 may cause ab-
normal HDL metabolism through mis-regulation of signal
molecules in BA. For example, CCK or chenodeoxycholic
acid (CDCA) positively influences BA metabolism (Figure 3
(5)). When dietary lipids and other nutrients arrive in
the gut, cholecystokinin (CCK) secreted from the small
intestine stimulates BA secretion from the gall bladder to
the gut. The majority of the BA is re-absorbed into the
liver via enterohepatic circulation and the reminder is ex-
creted through feces. CDCA is a major component in the
BA and functions as a signaling molecule in HDL metab-
olism. CDCA binds to the farnesoid X-activated receptor
(FXR) that regulates lipid and cholesterol metabolism
[37]. FXR, a member of the nuclear hormone receptor
superfamily, forms a heterodimer with the retinoid X re-
ceptor (RXR). The FXR/RXR heterodimer functions as a
transcription factor that positively influences phospholipid
transfer protein (PLTP) mRNA transcription (Figure 3(6)).
Co-transfecting FXR and RXR expression plasmids and
CDCA treatment in monkey kidney cells increased PLTP
promoter activity. Cholic acid, another major component
in the BA, is involved in PLTP regulation [38]. Mice fed a
chow diet with cholic acid exhibited increased hepatic
PLTP mRNA levels. PLTP is an important factor for HDL
conversion and positively influence HDL level (Figure 3
(7)). Mice lacking the Pltp gene displayed reduced levels
of HDL cholesterol (65%) and APOA1 protein (85%)
(Figure 3(8)) compared to wild-type control mice [39].
Figure 3 Integrated physiological model of the molecular and metabolic networking between PCSK members. The figure illustrates the
role of PCSK1, PCSK3, PCSK5, PCSK6, and PCSK9 in the lipoprotein triad (HDL, LDL and VLDL). HDL level and function are synergistically regulated
by those metabolic factors: glucose, triglyceride (TG) and BA metabolism. Arrows with 2 different types of lines indicate the relationship between
factors: dotted lines with arrow indicate a “negative influence.” For example, LDLR decreases HDL cholesterol concentration (Figure 3(4)). In
contrast, solid lines with arrow indicate a “positive influence.” For example, CCK secreted from the small intestine stimulates BA secretion
(Figure 3(5)). Solid lines without arrow indicate two major ways of reverse cholesterol transport (RCT). First, cholesteryl ester transfer protein
(CETP) exchanges cholesterol in LDL by TG in HDL (Figure 3(9)). Second, HDL takes up cholesterol that is accumulated in macrophage foam cells
inside the blood vessel wall (Figure 3(10)). Cholesterol-carrying HDL returns to the liver to recycle or excrete the cholesterol.
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the PLTP gene impairs HDL conversion [40,41].
Maintenance of normal HDL metabolism is critical for
normal physiological function of HDL. Reverse choles-
terol transport (RCT) is an anti-atherogenic process that
occurs between lipoproteins (Figure 3(9)) or between li-
poproteins and macrophage foam cells (Figure 3(10)).
The efficiency of RCT can be analyzed by measuring the
amount of cholesterol in medium and cells. EL defi-
ciency affects efficiency of cholesterol efflux from macro-
phages. EL knockdown using small hairpin (sh) RNA
reduced APOA1-mediated cholesterol efflux [42]. PCSK9
KO decreases the efficiency of cholesterol efflux [12].
Treating PCSK9 KO mouse serum to cultured macrophage
foam cells exhibits decreased cholesterol efflux. Thus,
abnormal HDL regulation caused by genetic alterations
in some PCSK members may interfere with reverse chol-
esterol transport efficiency.
Normal insulin processing, which influences glucose
and triglyceride metabolism, is critical for maintaining
normal HDL metabolism [35]. Type II diabetic patients
show decreased small HDL particles [43]. Hypertriglyc-
eridemia patients with hyperglycemic phenotype exhibited
increased TG-rich HDL with lower stability and shorter
plasma residence time compare to cholesterol-rich HDL
(Figure 2(11)) [44]. The TG-rich HDL is rapidly catabolized,which subsequently decreases plasma HDL cholesterol
concentration [45]. Another potential cause of abnormal
HDL metabolism is glycation that leads to conformation
changes of proteins. Glycation of amino-acid residues in
APOA1 alters its binding affinity to ATP-binding cassette
sub-family G member 1 (ABCG1) in the human acute
monocytic leukemia cell lines (THP-1). As a result, the abil-
ity of cholesterol efflux from THP-1 cells was significantly
reduced (< 70%) compared to unglycated APOA1 [46].
Conclusion and discussion
In this review, we summarize how PCSK1, 3, 5, 6, and 9
influence HDL cholesterol concentrations by regulating
modulators in various metabolic processes (Figure 4).
We also review the current understanding of how five
PCSK members are linked not only to abnormal HDL
metabolism, but also to other metabolic processes in-
cluding regulation of lipid, glucose, and BA. To explain
the complex relationships between the PCSK members
and various metabolic processes, an integrated physio-
logical point of view will be critical to improve our un-
derstanding about PCSK members. We propose a model
in which PCSK members play pivotal roles in HDL,
non-HDL, glucose, insulin, BA, and TG regulation. For
example, PCSK1 influences lipoprotein, glucose, and BA




























































Figure 4 The role and action of PCSK members in regulating
HDL cholesterol concentration. The figure illustrates the role and
action of PCSK1, PCSK3, PCSK5, PCSK6, and PCSK9 in HDL cholesterol
concentration. Arrows with 2 different types of lines indicate the
relationship between factors: solid lines with arrow indicate a
“positive influence” and dotted line with arrow indicates a “negative
influence.” Solid line without arrow indicates a “no influence.” PCSK1
negatively influences serum APOA1 level, but does not influence
HDL cholesterol concentration, PCSK3, 5 and 6 positively influences
HDL cholesterol concentration by modulating enzymatic activities of
EL and LPL. PCSK9 positively influences HDL cholesterol
concentration by regulating APOE-containing HDL subfraction level
through LDLR.
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tabolism by modulating the activity of EL, LPL, and the
level of LDLR through PCSK9 cleavage. PCSK9 influ-
ences glucose and lipoprotein metabolisms by regulating
insulin and LDLR receptor degradation.
Some of the PCSK members have functional redun-
dancy by processing common substrates: insulin by
PCSK1 and PCSK9; CCK by PCSK1 and PCSK5; TG li-
pases (EL and LPL) by PCSK3, PCSK5, and PCSK6. In
the latter case, all 3 PCSKs modulate the activity of the
TG lipases, but the efficiency of the modulation varies:
for EL inactivation PCSK6 has the highest efficiency
while PCSK3 has the lowest efficiency; for LPL activa-
tion PCSK3 has the highest efficiency while PCSK5 has
the lowest efficiency [11]. The PCSK members also regulate
one another. The activity of PCSK9 is negatively influenced
by two other PCSK members: PCSK3 (Figure 3(12))
and PCSK5 (Figure 3(13)). PCSK3 cleaves PCSK9 at
the Arg218-Gln219 peptide bond in HEK293 cells, andPCSK5 cleaves the same bond, but with lower efficiency
compared to PCSK3 [11].
The biology and therapeutic targeting of PCSK mem-
bers has been recently reviewed [1]. Particularly, thera-
peutic inhibition of PCSK9 has been proven to be a
promising pro-atherogenic LDL cholesterol-lowering treat-
ment. Co-treatment of PCSK inhibitors with drugs that
suppress cholesterol synthesis is even more effective in
reducing LDL cholesterol in hypercholesterolemia patients
[47]. Also, PCSK9 inhibition in the patients did not cause
negative impact on anti-atherognic HDL cholesterol con-
centration in early-phase clinical trial phase I or phase II
[47-49]. However, the effect of PCSK9 inhibition on HDL
cholesterol concentration is controversial. Some studies
used mice showed that PCSK9 inhibition decreases HDL
cholesterol concentration [12,32]. Because HDL cholesterol
regulation and metabolism differ between mouse and
human, we speculate that in human, although the inhib-
ition of PCSK9 affects LDLR level, it might not cause
strong enough effect to see significant measurable impact
on HDL cholesterol concentration. In humans, cholesterol
ester transfer protein (CETP) is a critical factor for regu-
lating HDL cholesterol concentration by transferring chol-
esterol from HDL to non-HDL particles. In mice lacking
CETP, cholesterol is enriched in APOE-containing HDL
particles and the particles are cleared through LDLR. In
other words, the effect of an increase of LDLR level by
PCSK9 inhibition on HDL cholesterol concentration in
humans might be smaller relative to its effect in mice. At
the same time, studies in nonhuman primates, which have
CETP and have similar HDL cholesterol metabolism to
humans in comparison to mice, show inconsistent results
in regards to the effect of PCSK9 inhibition on HDL chol-
esterol concentration [34,50]. Treatment with neutralizing
antibody against PCSK9 for the first 7 days of treatment
decreased HDL cholesterol concentration [34]. Meanwhile,
knockdown of PCSK9 by RNAi did not decrease HDL
cholesterol concentration [50]. The data from these studies
suggest that there are likely to be other factors causing the
inconsistent results between studies. First, it is possible that
the inconsistent results between studies might be caused
by the dosage of PCSK9 inhibition. Knockout of PCSK9
in mice [12,32] decreased HDL cholesterol concentrations
and knockdown of PCSK9 by RNAi [50] and over-
expression of PCSK9 by adenovirus [51] did not decrease
HDL cholesterol concentrations. Second, it is also possible
that whether or not PCSK9 targeting directs liver might
cause the inconsistent results. Liver-specific siRNA silen-
cing [50] and overexpression of PCSK9 by adenovirus,
which is known to primarily target the liver, do not de-
crease HDL cholesterol concentration. PCSK9 in other
tissues remains unaffected and might contribute to the
lack of decreased HDL cholesterol concentration. The
no change in HDL cholesterol concentration despite the
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expression [51] remains unclear and additional studies
would be needed to address this observation. If the
method is indeed the cause of the variation in HDL
cholesterol, then additional studies may provide valuable
information about the effectiveness of different methods.
At the same time, the use of neutralizing antibodies
against PCSK9 in several clinical trials [47-49] show no
negative impact on HDL cholesterol concentration. Con-
sidering the importance of PCSK9 as a promising thera-
peutic target, it will be important to understand whether
the inconsistent results are due to different dosage (knock-
out versus knockdown), CETP (presence vs absence), or
target (gene vs protein; liver vs organism). The molecular
and physiological functions of PCSK members in HDL
metabolism are likely more complex than we currently
know. In particular, our understanding of compensatory
mechanisms between PCSK members is also limited. We
look forward to continued studies that will improve our
understanding and allow more precise pharmacological
regulation of PCSK for the treatment of metabolic disease.
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